Inhibitory Effects of Pirfenidone on Dendritic Cells and Lung Allograft Rejection
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Transplantation
Reference32 articles.
1. . Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.;Azuma;Am J Respir Crit Care Med,2005
2. . Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment.;Azuma;Respir Res,2011
3. . Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.;Nagai;Intern Med,2002
4. . Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study.;Raghu;Am J Respir Crit Care Med,1999
5. . Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model.;Liu;J Thorac Cardiovasc Surg,2005
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Add-on therapy for pulmonary fibrosis, a forthcoming era with implications for practice: the BI 101550 and RELIEF trials;Breathe;2023-09
2. Investigating the possible mechanisms of pirfenidone to be targeted as a promising anti-inflammatory, anti-fibrotic, anti-oxidant, anti-apoptotic, anti-tumor, and/or anti-SARS-CoV-2;Life Sciences;2022-11
3. The role of immune response in the pathogenesis of idiopathic pulmonary fibrosis: far beyond the Th1/Th2 imbalance;Expert Opinion on Therapeutic Targets;2022-07-03
4. Lung Fibrosis and Fibrosis in the Lungs: Is It All about Myofibroblasts?;Biomedicines;2022-06-15
5. The Efficacy and Safety of Pirfenidone Combined With Immunosuppressant Therapy in Connective Tissue Disease-Associated Interstitial Lung Disease: A 24-Week Prospective Controlled Cohort Study;Frontiers in Medicine;2022-05-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3